Manager TitleAgeSince
Chief Executive Officer 53 29/08/2022
Director of Finance/CFO 55 01/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 31/08/2015
Chairman 71 14/04/2021
Director/Board Member 59 14/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.88%+8.00% - - 1.51M
+4.16%+4.16%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+1.96%+9.19%+52.66% 31.07B
-3.11%+0.09%+33.57%+24.94% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +0.21%-0.78%+52.29%+123.16% 43.73B
Weighted average by Cap. +0.21%-0.94%+56.43%+132.24%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4
  1. Stock Market
  2. Stocks
  3. AMNI Stock